BioSpace News Archive

The opening shortens the commute for residents of Upland and of most nearby cities who are seeking leading-edge oncology treatment

The market will accelerate at a CAGR of over 5% between 2019-2023

Three hospital associations in New Jersey, Ohio and Pennsylvania announced the creation of Q3 Health Innovation Partners, a new joint venture to improve health quality and patient safety.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the first patient has been enrolled in the REFINE-ALS clinical study, designed to identify and measure specific biomarkers and clinical assessments in up to 300 people with amyotrophic lateral sclerosis (ALS) in the United States who have begun treatment on RADICAVA® (edaravone).

Event recognizes individuals dedicated to empowering people affected by myeloproliferative neoplasms

Healthcare marketers now have a new privacy and HIPAA compliant way to create accurate customer segments and targeting models from Prosper’s new Model Factory on AWS SageMaker platform.

Advocates for patients with Lyme disease were on Capitol Hill Tuesday to raise awareness about the growing threat to public health of the tick-borne disease, including the launch of a new national organization dedicated to increasing federal funding for better diagnosis and treatment options.

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with a primary focus in hematology and oncology, announced today that the company submitted an updated Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ROLONTIS (eflapegrastim).

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report business results for the third quarter of 2019 after 5:00 p.m. ET on Tuesday, November 5, 2019.

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, will report its third quarter 2019 financial results on Wednesday, November 6, 2019 after the U.S. financial markets close.